A Phase 1 Study, Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of HS-10529 Monotherapy in KRAS G12D Patients With Advanced Solid Tumors
Latest Information Update: 16 May 2025
At a glance
- Drugs HS 10529 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Jiangsu Hansoh Pharmaceutical
Most Recent Events
- 16 May 2025 New trial record